Table 1: Recurrence across surveyed HSCT programs.

Monitored process (Figure 1) / Name of the indicator / Overall frequency / Number of center using this indicator / Type of indicator / Proportion of cases in which this indicator was implemented for JACIE preparation
MANAGEMENT PROCESSES
M1 / Quality objectives completed / 1/293 / 1/32 / outcome / 1/1
M1 / Number of quality report / 1/293 / 1/32 / outcome / 1/1
M1 / Number of quality project achieved among total projects implemented per year / 1/293 / 1/32 / outcome / 1/1
M1 / Quality management meetings / 1/293 / 1/32 / outcome / 1/1
M2 / Conduct of audits / 8/293 / 8/32 / process / 8/8
M2 / Report of severe adverse events or accidents / 21/293 / 16/32 / process / 14/20
M2 / Descriptive statistics activity / 25/293 / 8/32 / activity / 22/25
M3 / Healthcare consultant satisfaction / 6/293 / 6/32 / outcome / 2/6
OPERATING PROCESSES
O2 / Proportion of qualified persons for collection / 1/293 / 1/32 / process / 0/1
O2 / Number of patients who entered the program and were finally not transplanted (autologous PBSCT) / 1/293 / 1/32 / process / 1/1
O2 / Time to find an unrelated compatible donor / 1/293 / 1/32 / outcome / 1/1
O2 / Origin of the unrelated donor for allograft per year / 1/293 / 1/32 / outcome / 1/1
O2 / Number of confirmation of HLA typing ordered per patient (case of allograft with unrelated donor) / 2/293 / 2/32 / process / 2/2
O3 / Follow-up of infection disease testing / 1/293 / 1/32 / process / 1/1
O3 / Hematocrit of collection product / 1/293 / 1/32 / outcome / 1/1
O3 / Unprogrammed hospitalisation (complications) during mobilisation therapy / 1/293 / 1/32 / process / 1/1
O3 / Apheresis not performed due to insufficient mobilization / 1/293 / 1/32 / outcome / 1/1
O3 / Number of collection contamined with polynuclear / 2/293 / 2/32 / outcome / 2/2
O3 / Complications during collection procedure / 2/293 / 2/32 / process / 2/2
O3 / Quality of collected product not considering bacterial contamination / 2/293 / 2/32 / process / 0/2
O3 / Proportion of persons adressed to apheresis facility who can be collected / 4/293 / 3/32 / outcome / 4/4
O3 / Apheresis efficiency (criteria varies in different facilities) / 10/293 / 9/32 / process / 8/10
O3 / Positive microbiology in collected cell products / 11/293 / 11/32 / process / 6/11
O3 / Collection of HSC/target collection CD34+ cells reached? / 13/293 / 13/32 / outcome / 10/13
O4 / Donor's follow-up / 1/293 / 1/32 / process / 0/1
O5 / Number of stem cell bags with problematic freezing procedure / 1/293 / 1/32 / outcome / 1/1
O5 / Follow-up of the time to freeze products after collection / 1/293 / 1/32 / process / 1/1
O5 / % of poor performance in external quality control / 1/293 / 1/32 / process / 1/1
O5 / Date of cell processing / 1/293 / 1/32 / outcome / 1/1
O5 / Delay in which quality controls are made available for CTPs collected at a distant site from the processing facility / 1/293 / 1/32 / process / 0/1
O5 / Follow-up of CTP storage / 2/293 / 1/32 / process / 2/2
O5 / Monitoring Freezing methods / 2/293 / 1/32 / outcome / 2/2
O5 / Request of cryopreserved product / 2/293 / 2/32 / outcome / 2/2
O5 / Microbial contamination during processing / 12/293 / 11/32 / process / 7/12
O5 / Cell recovery post thawing / 15/293 / 9/32 / process / 10/15
O6 / Tracking / measuring the rate of compliance with the information about diagnosis and treatment in the outpatient department / 1/293 / 1/32 / outcome / 0/1
O6 / Number of patients included in a clinical research protocol/ number of diagnosis / 1/293 / 1/32 / outcome / 0/1
O6 / Apheresis not performed due to different criterias(relapse, progression or insufficient general state) / 3/293 / 1/32 / outcome / 3/3
O7 / Proportion of delayed chemotherapies in relation with logistical issues or with patient status / 1/293 / 1/32 / outcome / 0/1
O8 / Proportion of prescribed investigations in transplanted patients / 1/293 / 1/32 / outcome / 1/1
O8 / Invasive fungal infections / 2/293 / 2/32 / outcome / 1/2
O8 / Days with fever ≥ 38°C / 2/293 / 2/32 / process / 2/2
O8 / Duration of stay on intensive care unit / 2/293 / 2/32 / process / 1/2
O8 / % of CVC related complications / 3/293 / 2/32 / outcome / 3/3
O8 / Duration of aplasie / 4/293 / 4/32 / outcome / 4/4
O8 / Number of PLT or red cells units transfused in the first 100 days post SCT / 4/293 / 3/32 / outcome / 3/4
O8 / Incidence of GVHD / 4/293 / 4/32 / outcome / 2/4
O8 / Positive blood culture yes/no / 5/293 / 5/32 / outcome / 5/5
O8 / TRM / 23/293 / 18/32 / outcome / 20/23
O8 / Median time in days until engraftment (granulocyts,platelets and neutrophils) / 17/293 / 14/32 / outcome / 15/17
O9 / Median survival at 2 years post-transplantation (auto PBSCT) of patients transplanted during the last 5 years / 1/293 / 1/32 / outcome / 1/1
O9 / Lost to follow-up / 1/293 / 1/32 / outcome / 0/1
O9 / Follow up of effectiveness of quality of care and supportive treatment post transplantation / 2/293 / 1/32 / process / 0/2
O9 / TRM at least one year post transplant / 3/293 / 2/32 / outcome / 3/3
O9 / Number of patients hospitalised for post transplant complication / 3/293 / 3/32 / outcome / 3/3
O9 / Overall survival / 4/293 / 4/32 / outcome / 3/4
O9 / Relapse rate / 5/293 / 4/32 / outcome / 3/5
O9 / Length of hospital stay / 7/293 / 7/32 / process / 7/7
O10 / Donor satisfaction survey / 1/293 / 1/32 / outcome / 1/1
O10 / Complaints / 2/293 / 2/32 / outcome / 2/2
O10 / Patient satisfaction / 12/293 / 11/32 / outcome / 8/12
SUPPORT PROCESSES
S1 / Document deficiencies / 1/293 / 1/32 / process / 0/1
S2 / Publications of medical personal / 1/293 / 1/32 / outcome / 1/1
S2 / Training and competencies of medical and paramedical personal / 9/293 / 8/32 / process / 8/9
S3 / Infrastructure monitoring / 5/293 / 5/32 / process / 2/5
S3 / Equipement monitoring / 3/293 / 3/32 / process / 2/3
S4 / Budget allogeneic clinical unit / 1/293 / 1/32 / process / 0/1
S4 / Collection of stem cells during WE or holidays / 1/293 / 1/32 / outcome / 1/1
S4 / Costs/ procedure points / 1/293 / 1/32 / process / 1/1